Chairman and CEO of Abbott Laboratories (NYSE:ABT), recently sold a significant portion of his holdings in the company. According to a Form 4 filing with the Securities and Exchange Commission, Ford ...

The last few weekends have been roiled by headlines. Here's why we took a different direction on this medical stock this week ...

Abbott Laboratories posts total worldwide sales of $10.97 billion for the quarter ended Dec. 31, missing Wall Street estimates of $11.03 billion.

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Abbott is expected to post earnings of $1.07 ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Mizuho raised their price objective on Abbott Laboratories from $115.00 to $130.00 and gave the stock a “neutral” rating in a research note on Thursday, October 17th. Argus raised shares of ...

Shares of Abbott Laboratories ABT shed 1.18% to $111.10 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.83% to ...

The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the consensus estimates of $11.01 billion and ...

which have created an overhang on the company's stock price. One of the most significant challenges facing Abbott Laboratories is the ongoing litigation related to necrotizing enterocolitis (NEC ...